Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications




Bionano Announces 2024 Symposium: Four Consecutive Days of OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its 2024 Symposium, the quintessential event for the optical genome mapping (OGM) community. The event is an opportunity for OGM users to present their progress to the world. 2024 Symposium will feature four consecutive days of OGM presentations delivered by 27 different customers worldwide across a wide range of applications in cancer, cell and gene therapy, and constitutional genetic disease. The Symposium will take place virtually from January 22 to 25, 2024. Each day will feature user presentations, a live panel with Q&A, and scientific posters within the virtual exhibition hall. On day 2, Bionano will unveil a new product expected to advance cytogenetics and structural variant analysis.

“At Bionano, we are working to transform the way the world sees the genome,” said Erik Holmlin, PhD, president and chief executive officer of Bionano. “Symposium is our platform event for the community of OGM users to share their experiences with OGM and how it can be used to reveal more answers for research applications. What impresses me most about the lineup for 2024 is the sheer breadth of topics, ranging from the use of OGM in prenatal and postnatal testing, to homologous recombination deficiency (HRD) analysis in breast cancer and the use of OGM in drug development through cell and gene therapy.”

“We were thrilled with the engagement of the OGM community at 2023 Symposium, with participants from 114 different countries. We believe our customers around the world have made tremendous progress with the implementation of OGM in their laboratories since last year. The lineup of researchers for our 2024 Symposium is our most exciting to date, with 27 global experts detailing their use of OGM to drive discoveries across a number of clinical research applications,” said Alka Chaubey, PhD, FACMG, chief medical officer at Bionano.

Each session of 2024 Symposium will start at 7:00 am PST and will last approximately 3 hours. After the scientific presentations, the speakers will join a live panel discussion and Q&A moderated by Dr. Chaubey. In addition, each day will feature a scientific poster exhibit. Below is an overview of the presentation topics for each day of the event.

Monday, January 22: New Standards in Hematological Malignancies

Global researchers studying genomic variants involved in hematologic malignancies will discuss their experience publishing a framework to guide OGM implementation as part of an international consortium. Speakers will also highlight the use of new tools, including VIA™ software, to find more pathogenic chromosomal aberrations in hematological malignancy samples while also simplifying laboratory workflows.

Tuesday, January 23: New Frontiers in Oncology
Scientists and clinicians from leading hospitals and medical research institutions in the United States, India and Europe will discuss OGM’s utility for the assessment of genomic aberrations in a wide range of hematological malignancies and solid tumors. Experts will present results from a prospective study on the use of OGM in hematological malignancy samples. The final presentation of the day will feature Bionano leadership unveiling a major new product, followed by a live discussion and question and answer session.

Wednesday, January 24: Advances in Constitutional Applications
Researchers will present their experiences using OGM to uncover genetic variation that contributes to rare undiagnosed genetic disease, developmental disorders and reproductive disorders. Presentations will demonstrate how the analysis of structural variation data from OGM may increase the likelihood of identifying actional pathogenic variants that can help solve unresolved cases. Data from large multi-site studies focusing on prenatal and postnatal applications will be presented.

Thursday, January 25: OGM in Cell and Gene Therapy
Presentations will center on OGM’s potential to serve as a genomic integrity tool for cell and gene therapy applications, supporting the development of in vivo gene therapies. Panelists will cover OGM’s ability to screen cell lines for genomic instability and off-target events associated with genome editing.

2024 Symposium registration is open to all and there is no charge for attending this event. Register today at https://bionanosymposium2024.vfairs.com/.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology. For more information, visit www.bionano.comwww.bionanolaboratories.com or www.purigenbio.com

Unless specifically noted otherwise, Bionano’s OGM products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano

This press release contains forward-looking statements contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “can,” “may,” “potential,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances and the negatives thereof) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the anticipated benefits of the 2024 Symposium, the potential for OGM to be adopted for applications discussed at the 2024 Symposium, and the ability and utility of OGM to be adopted as a cytogenetic tool for analysis of oncology, including heme malignancies and solid tumors, constitutional genetic diseases or samples associated with cell bioprocessing and other applications discussed at the 2024 Symposium. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of geopolitical and macroeconomic developments, such as recent and future bank failures, the ongoing Ukraine-Russia conflict, related sanctions, the Israel-Hamas war, and any global pandemics, on our business and the global economy; challenges inherent in developing, manufacturing and commercializing products; our ability to further deploy new products and applications and expand the markets for our technology platforms; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure of future study results to support those reported and discussed at the 2024 Symposium; future study results that contradict the results discussed and reported at the 2024 Symposium; failure of OGM to be adopted as a cytogenetic tool for analysis of oncology, including heme malignancies and solid tumors, constitutional genetic diseases or samples associated with cell bioprocessing and other applications discussed at the 2024 Symposium; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general; our expectations and beliefs regarding future growth of the business and the markets in which we operate; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern”; and including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2022 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We are under no duty to update any of these forward-looking statements after the date they are made to conform these statements to actual results or revised expectations, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date the statements are made. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements contained in this press release.

CONTACTS

Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com